Fattori della coagulazione, apolipoproteine e rischio cardiovascolare

Livelli plasmatici elevati del complesso fattore VIIa-Antitrombina e dell'apolipoproteina CIII sono associati ad elevata generazione di fattore X attivato e di trombina in pazienti ischemici. E' in studio, anche attraverso l'impiego di inibitori oligonucleotidici di sintesi (aptameri), il meccanismo biochimico attraverso cui tali macromolecole causano ipercoagulabilità e decessi fra i pazienti.

 

 

 

 

Pubblicazioni:

 

Basophil Blood Cell Count Is Associated With Enhanced Factor II Plasma Coagulant Activity and Increased Risk of Mortality in Patients With Stable Coronary Artery Disease: Not Only Neutrophils as Prognostic Marker in Ischemic Heart Disease.

Pizzolo F, Castagna A, Olivieri O, Girelli D, Friso S, Stefanoni F, Udali S, Munerotto V, Baroni M, Cetera V, Luciani GB, Faggian G, Bernardi F, Martinelli N.J Am Heart Assoc. 2021 Feb;10(5):e018243.

doi: 10.1161/JAHA.120.018243.

 

Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease. Baroni M, Martinelli N, Lunghi B, Marchetti G, Castagna A, Stefanoni F, Pinotti M, Woodhams B, Oliviero O, Bernardi F.

Thromb Res. 2020 Mar 14;189:140-146.

doi: 10.1016/j.thromres.2020.03.007.

 

The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII. Andersen E, Chollet ME, Baroni M, Pinotti M, Bernardi F, Skarpen E, Sandset PM, Skretting G.

Cell Biosci. 2019 Aug 27;9:69.

doi: 10.1186/s13578-019-0333-8.

 

Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation. Martinelli N, Baroni M, Castagna A, Lunghi B, Stefanoni F, Tosi F, Croce J, Udali S, Woodhams B, Girelli D, Bernardi F, Olivieri O.

Thromb Haemost. 2019 Feb;119(2):192-202

doi: 10.1055/s-0038-1676817

 

Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study. Martinelli N, Girelli D, Baroni M, Guarini P, Sandri M, Lunghi B, Tosi F, Branchini A, Sartori F, Woodhams B, Bernardi F, Olivieri O.

J Thromb Haemost. 2016 Apr;14(4):655-66.

doi: 10.1111/jth.13274.

 

Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation. Baroni M, Pavani G, Pinotti M, Branchini A, Bernardi F, Camire RM.

Biochim Biophys Acta. 2015 Oct;1854(10 Pt A):1351-6.

doi: 10.1016/j.bbapap.2015.05.012

 

Coagulation factor VII variants resistant to inhibitory antibodies. Branchini A, Baroni M, Pfeiffer C, Batorova A, Giansily-Blaizot M, Schved JF, Mariani G, Bernardi F1, Pinotti M.

Thromb Haemost. 2014 Nov;112(5):972-80.

doi: 10.1160/TH14-03-0198.

 

Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele. Olivieri O, Martinelli N, Baroni M, Branchini A, Girelli D, Friso S, Pizzolo F, Bernardi F.

J Am Heart Assoc. 2013 Nov 15;2(6):e000440.

doi: 10.1161/JAHA.113.000440.